南新制药
(688189)
| 流通市值：19.43亿 | | | 总市值：19.43亿 |
| 流通股本：2.74亿 | | | 总股本：2.74亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 111,835,236.68 | 744,601,965.89 | 562,058,852.86 | 513,749,677.21 |
| 营业收入 | 111,835,236.68 | 744,601,965.89 | 562,058,852.86 | 513,749,677.21 |
| 二、营业总成本 | 89,089,221.39 | 628,167,166.97 | 508,120,982.75 | 434,419,987.44 |
| 营业成本 | 46,254,672.74 | 113,738,277.1 | 51,271,168 | 34,519,546.76 |
| 税金及附加 | 1,559,205.44 | 10,243,350.2 | 8,064,174.35 | 6,924,477.31 |
| 销售费用 | 28,765,178.83 | 370,945,370.73 | 341,793,551.23 | 309,750,316.95 |
| 管理费用 | 6,261,182.38 | 53,385,073.75 | 39,315,430.43 | 29,092,243.32 |
| 研发费用 | 6,826,875.34 | 74,863,912.65 | 63,925,857.68 | 49,188,383.4 |
| 财务费用 | -577,893.34 | 4,991,182.54 | 3,750,801.06 | 4,945,019.7 |
| 其中:利息费用 | 1,319,817.83 | 15,248,017.68 | 11,215,324.3 | 8,807,437.09 |
| 其中:利息收入 | 2,954,779.31 | 10,769,229.28 | 9,065,764.38 | 5,399,460.28 |
| 加:投资收益 | - | -14,911,680.82 | -10,090,896.5 | -10,090,896.5 |
| 资产处置收益 | - | 174,757.58 | - | - |
| 资产减值损失(新) | -2,932,820.04 | -8,803,136.36 | -6,786,099.94 | -3,841,971.79 |
| 信用减值损失(新) | -15,259,067.82 | -91,542,482.44 | -41,990,781.12 | -38,566,620.29 |
| 其他收益 | - | 6,059,974.22 | - | - |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 4,554,127.43 | 7,412,231.1 | -4,929,907.45 | 26,830,201.19 |
| 加:营业外收入 | 529,859.87 | 1,019,616.86 | 3,854,352.04 | 1,803,207.7 |
| 减:营业外支出 | - | 824,593.1 | 824,593.1 | 600 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 5,083,987.3 | 7,607,254.86 | -1,900,148.51 | 28,632,808.89 |
| 减:所得税费用 | 406,741.49 | 1,652,483.47 | -2,898,608.13 | -4,054,787.7 |
| 六、净利润 | 4,677,245.81 | 5,954,771.39 | 998,459.62 | 32,687,596.59 |
| 持续经营净利润 | 4,677,245.81 | 5,954,771.39 | 998,459.62 | 32,687,596.59 |
| 归属于母公司股东的净利润 | 3,766,508.55 | 3,751,487.27 | 650,517.07 | 28,408,196.09 |
| 少数股东损益 | 910,737.26 | 2,203,284.12 | 347,942.55 | 4,279,400.5 |
| (一)基本每股收益 | 0.01 | 0.01 | 0 | 0.1 |
| (二)稀释每股收益 | 0.01 | 0.01 | 0 | 0.1 |
| 九、综合收益总额 | 4,677,245.81 | 5,954,771.39 | 998,459.62 | 32,687,596.59 |
| 归属于母公司股东的综合收益总额 | 3,766,508.55 | 3,751,487.27 | 650,517.07 | 28,408,196.09 |
| 归属于少数股东的综合收益总额 | 910,737.26 | 2,203,284.12 | 347,942.55 | 4,279,400.5 |
| 公告日期 | 2024-04-30 | 2024-03-26 | 2023-10-31 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |